Although HIV-1 RNA levels are measured at the time of initial diagnosis, the results are not used for the clinical follow-up of the patients. This study evaluates the prognostic value of the baseline HIV-1 RNA levels (above or below 10,000 copies/ml) on rate of disease progression, among antiretroviral therapy (ART)-naive patients in Botswana. A prospective cohort of 436 HIV-infected ART-naive adults with baseline CD4 〉 400 cells/mm(3) were followed quarterly for 5 years in an urban clinic in Botswana. Baseline HIV-1 RNA levels and longitudinal CD4(+) T-cell count data were analyzed, using mixed-effects regression jointly modeled with the times to a composite endpoint defined by AIDS-defining clinical conditions or death. During 1,547 person-years (PYs) follow-up time, 106 individuals became eligible for ART initiation (incidence rate: 0.07 PYs) and 6 participants died of AIDS-related illness. There were 203 (47%) individuals with baseline HIV-1 RNA 〈10,000 copies/ml and 233 (53%) individuals with baseline RNA 〉10,000 copies/ml. The slope of the predicted CD4 trajectory for individuals with baseline HIV-1 RNA 〉10,000 copies/ml is 30% steeper than that for those with baseline RNA 〈10,000. The hazard of reaching the composite endpoint for the individuals with baseline HIV-1 RNA 〉10,000 copies/ml was 2.3 (95% confidence interval: 1.5-3.0) times higher than that for those with baseline HIV-1 RNA 〈10,000 copies/ml. CD4 decline in individuals with HIV-1 RNA 〉10,000 copies/ml is much faster than that in those with RNA 〈10,000. The elevated HIV-1 RNA can be used as a marker to identify individuals at risk of faster disease progression.
Type of Publication:
Journal article published